{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ma S"],"funding":["National Natural Science Foundation of China"],"pagination":["104"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11024067"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["73(6)"],"pubmed_abstract":["Few studies have reported the associations of granulocyte colony-stimulating factor (G-CSF) with cytokine release syndrome (CRS), neurotoxic events (NEs) and efficacy after chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We present a retrospective study of 67 patients with R/R B-ALL who received anti-CD19 CAR T-cell therapy, 41 (61.2%) patients received G-CSF (G-CSF group), while 26 (38.8%) did not (non-G-CSF group). Patients had similar duration of grade 3-4 neutropenia between the two groups. The incidences of CRS and NEs were higher in G-CSF group, while no differences in severity were found. Further stratified analysis showed that the incidence and severity of CRS were not associated with G-CSF administration "],"journal":["Cancer immunology, immunotherapy : CII"],"pubmed_title":["Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia."],"pmcid":["PMC11024067"],"funding_grant_id":["82270232"],"pubmed_authors":["Xu K","Ma S","Lu W","Qi K","Li D","Cao J","Zhu F","Sang W","Zhao M","Yan Z","Li Z","Qi Y","Niu M","Wang Y","Cheng H"],"additional_accession":[]},"is_claimable":false,"name":"Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia.","description":"Few studies have reported the associations of granulocyte colony-stimulating factor (G-CSF) with cytokine release syndrome (CRS), neurotoxic events (NEs) and efficacy after chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We present a retrospective study of 67 patients with R/R B-ALL who received anti-CD19 CAR T-cell therapy, 41 (61.2%) patients received G-CSF (G-CSF group), while 26 (38.8%) did not (non-G-CSF group). Patients had similar duration of grade 3-4 neutropenia between the two groups. The incidences of CRS and NEs were higher in G-CSF group, while no differences in severity were found. Further stratified analysis showed that the incidence and severity of CRS were not associated with G-CSF administration ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2025-04-22T20:48:27.226Z","creation":"2025-04-06T03:17:03.852Z"},"accession":"S-EPMC11024067","cross_references":{"pubmed":["38630258"],"doi":["10.1007/s00262-024-03661-1"]}}